Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in J Thromb Thrombolysis

Retrieve available abstracts of 55 articles:
HTML format

Single Articles

    March 2023
  1. CEREJA F, Alves M, Ferreira JJ, Caldeira D, et al
    Atrial fibrillation risk on Parkinson's disease - a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2023 Mar 25. doi: 10.1007/s11239-023-02792.
    PubMed     Abstract available

  2. BERTEOTTI M, Gori AM, Giusti B, Fortini A, et al
    Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.
    J Thromb Thrombolysis. 2023 Mar 11. doi: 10.1007/s11239-023-02784.
    PubMed     Abstract available

    February 2023
  3. CLINE L, Generoso EMG, D'Apice N, Dellinger SK, et al
    Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance < 30 mL/min.
    J Thromb Thrombolysis. 2023;55:355-364.
    PubMed     Abstract available

  4. SIEGAL DM, Freedman D, Ansell J
    Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
    J Thromb Thrombolysis. 2023;55:197-202.
    PubMed     Abstract available

  5. COSTA LSD, Alsultan MM, Hincapie AL, Guo JJ, et al
    Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
    J Thromb Thrombolysis. 2023;55:339-345.
    PubMed     Abstract available

    January 2023
  6. DECAMILLO D, Haymart B, Kong X, Kaatz S, et al
    Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation.
    J Thromb Thrombolysis. 2023 Jan 30. doi: 10.1007/s11239-023-02777.
    PubMed     Abstract available

  7. JANSSON M, Sjalander S, Sjogren V, Bjorck F, et al
    Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
    J Thromb Thrombolysis. 2023 Jan 6. doi: 10.1007/s11239-022-02763.
    PubMed     Abstract available

  8. WANG K, Lu Y, Simegn MA, Xue H, et al
    Use of SAMe-TT(2)R(2) in a racially diverse anticoagulation clinic: prediction of optimal anticoagulation.
    J Thromb Thrombolysis. 2023;55:175-180.
    PubMed     Abstract available

  9. FELDEISEN D, Alexandris-Souphis C, Haymart B, Gu X, et al
    Higher OAK (Oral Anticoagulation Knowledge) score at baseline associated with better TTR (Time in Therapeutic Range) in patients taking warfarin.
    J Thromb Thrombolysis. 2023;55:141-148.
    PubMed     Abstract available

  10. POLZIN A, Helten C, Metzen D, Zako S, et al
    TAVR: nemesis of NOACs?
    J Thromb Thrombolysis. 2023;55:181-184.
    PubMed     Abstract available

  11. AMIRTABAR A, Vazquez SR, Saunders J, Witt DM, et al
    Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants.
    J Thromb Thrombolysis. 2023;55:185-188.
    PubMed     Abstract available

    December 2022
  12. WANG M, Yang Y, Luan M, Wang Y, et al
    Role of cerebral microbleeds in acute ischemic stroke and atrial fibrillation.
    J Thromb Thrombolysis. 2022 Dec 26. doi: 10.1007/s11239-022-02761.
    PubMed     Abstract available

  13. HANTRAKUN N, Wongcharoen W, Thiankhaw K, Norasetthada L, et al
    Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
    J Thromb Thrombolysis. 2022 Dec 9. doi: 10.1007/s11239-022-02747.
    PubMed     Abstract available

  14. CARBONE A, Bottino R, Attena E, Parisi V, et al
    Clinical impact of oral anticoagulation among octogenarians with atrial fibrillation and anaemia.
    J Thromb Thrombolysis. 2022 Dec 6. doi: 10.1007/s11239-022-02740.
    PubMed     Abstract available

    November 2022
  15. LIANOS I, Varlamos C, Benetou DR, Mantis C, et al
    Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention.
    J Thromb Thrombolysis. 2022 Nov 12. pii: 10.1007/s11239-022-02723.
    PubMed     Abstract available

    October 2022
  16. YE TTS, Siah QZ, Tan BYQ, Ho JSY, et al
    Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2022 Oct 3. pii: 10.1007/s11239-022-02713.
    PubMed     Abstract available

    September 2022
  17. SERRAO A, Malfona F, Assanto GM, Orellana MGC, et al
    Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies.
    J Thromb Thrombolysis. 2022 Sep 20. pii: 10.1007/s11239-022-02702.
    PubMed     Abstract available

    June 2022
  18. NOVAK AR, Shakowski C, Trujillo TC, Wright GC, et al
    Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2022 Jun 10. pii: 10.1007/s11239-022-02668.
    PubMed     Abstract available

    May 2022
  19. LIP GYH, Keshishian A, Kang A, Luo X, et al
    Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
    J Thromb Thrombolysis. 2022 May 17. pii: 10.1007/s11239-022-02660.
    PubMed     Abstract available

    April 2022
  20. MARTINEZ KA, Eckman MH, Pappas MA, Rothberg MB, et al
    Prescribing of anticoagulation for atrial fibrillation in primary care.
    J Thromb Thrombolysis. 2022 Apr 21. pii: 10.1007/s11239-022-02655.
    PubMed     Abstract available

  21. DING WY, Rivera-Caravaca JM, Marin F, Roldan V, et al
    Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.
    J Thromb Thrombolysis. 2022 Apr 15. pii: 10.1007/s11239-022-02638.
    PubMed     Abstract available

  22. FROL S, Hudnik LK, Sernec LP, Sabovic M, et al
    Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status.
    J Thromb Thrombolysis. 2022;53:607-615.
    PubMed     Abstract available

  23. DECAMILLO D, Haymart B, Barnes GD
    Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
    J Thromb Thrombolysis. 2022;53:601-606.
    PubMed     Abstract available

    February 2022
  24. POTERE N, Candeloro M, Porreca E, Marinari S, et al
    Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone.
    J Thromb Thrombolysis. 2022;53:346-351.
    PubMed     Abstract available

  25. MEADOR S, Dyke S, Togami J, Kuskov B, et al
    Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics.
    J Thromb Thrombolysis. 2022;53:436-445.
    PubMed     Abstract available

  26. GALLI M, Gargiulo G
    Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment.
    J Thromb Thrombolysis. 2022;53:495-498.

    January 2022
  27. BAI Y, Liu XY, Liu Y, Guo SD, et al
    Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients.
    J Thromb Thrombolysis. 2022 Jan 24. pii: 10.1007/s11239-021-02622.
    PubMed     Abstract available

    October 2021
  28. LV WH, Dong JZ, Du X, Hu R, et al
    Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
    J Thromb Thrombolysis. 2021 Oct 22. pii: 10.1007/s11239-021-02588.
    PubMed     Abstract available

  29. BEWERSDORF JP, Parmar N, Israel GM, Gettinger SN, et al
    Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.
    J Thromb Thrombolysis. 2021;52:854-862.
    PubMed     Abstract available

  30. CHEN Y, Zhang Y, Qu L, Huang W, et al
    Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure.
    J Thromb Thrombolysis. 2021;52:872-879.
    PubMed     Abstract available

  31. NISLY SA, Mihm AE, Gillette C, Davis KA, et al
    Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:817-827.
    PubMed     Abstract available

  32. SADIQ H, Hoque L, Shi Q, Manning G, et al
    SUPPORT-AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF.
    J Thromb Thrombolysis. 2021;52:808-816.
    PubMed     Abstract available

    September 2021
  33. PAPANASTASIOU A, Kartas A, Samaras A, Vrana E, et al
    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 25. pii: 10.1007/s11239-021-02571.
    PubMed     Abstract available

  34. WANG CL, Wu VC, Tu HT, Huang YT, et al
    Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 23. pii: 10.1007/s11239-021-02570.
    PubMed     Abstract available

  35. OBI CA, Bulsara K, Izard S, Delicce A, et al
    Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall.
    J Thromb Thrombolysis. 2021 Sep 4. pii: 10.1007/s11239-021-02555.
    PubMed     Abstract available

  36. CHEN J, Zhou M, Wang H, Zheng Z, et al
    Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score.
    J Thromb Thrombolysis. 2021 Sep 2. pii: 10.1007/s11239-021-02554.
    PubMed     Abstract available

    August 2021
  37. MENDOZA PA, McIntyre WF, Belley-Cote EP, Wang J, et al
    Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.
    J Thromb Thrombolysis. 2021 Aug 2. pii: 10.1007/s11239-021-02530.
    PubMed     Abstract available

  38. AFZAL S, Zaidi STR, Merchant HA, Babar ZU, et al
    Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting.
    J Thromb Thrombolysis. 2021;52:646-653.
    PubMed     Abstract available

  39. ROMOLI M, Marchetti G, Bernardini F, Urbinati S, et al
    Switching between direct oral anticoagulants: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:560-566.
    PubMed     Abstract available

  40. BASS ME, Kiser TH, Page RL 2nd, McIlvennan CK, et al
    Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus.
    J Thromb Thrombolysis. 2021;52:517-522.
    PubMed     Abstract available

    July 2021
  41. LI RJ, Caughey GE, Shakib S
    Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jul 24. pii: 10.1007/s11239-021-02528.
    PubMed     Abstract available

  42. KAO CC, Wang T, Parulekar AD
    Need for anticoagulation and use of direct oral anticoagulants in lung transplant recipients.
    J Thromb Thrombolysis. 2021;52:232-238.
    PubMed     Abstract available

  43. ROSSIER C, Spoutz P, Schaefer M, Allen A, et al
    Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management.
    J Thromb Thrombolysis. 2021;52:200-208.
    PubMed     Abstract available

  44. WALLVIK N, Renlund H, Sjalander A
    Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants.
    J Thromb Thrombolysis. 2021;52:315-323.
    PubMed     Abstract available

  45. SYLVESTER KW, Wagner C, Lewin A, Fanikos J, et al
    Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience.
    J Thromb Thrombolysis. 2021;52:158-160.

    June 2021
  46. LU X, Chen T, Liu G, Guo Y, et al
    Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jun 15. pii: 10.1007/s11239-021-02490.
    PubMed     Abstract available

    May 2021
  47. PIAZZA G, Hurwitz S, Goldhaber SZ
    Stroke risk factors and outcomes among hospitalized women with atrial fibrillation.
    J Thromb Thrombolysis. 2021 May 26. pii: 10.1007/s11239-021-02482.
    PubMed     Abstract available

  48. BERNAITIS N, Badrick T, Anoopkumar-Dukie S
    Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
    J Thromb Thrombolysis. 2021 May 7. pii: 10.1007/s11239-021-02466.
    PubMed     Abstract available

  49. GUNER A, Kalcik M, Gunduz S, Gursoy MO, et al
    The relationship between incomplete surgical obliteration of the left atrial appendage and thromboembolic events after mitral valve surgery (from the ISOLATE Registry).
    J Thromb Thrombolysis. 2021;51:1078-1089.
    PubMed     Abstract available

  50. MARCATTO L, Boer B, Sacilotto L, Olivetti N, et al
    Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range.
    J Thromb Thrombolysis. 2021;51:1043-1049.
    PubMed     Abstract available

    April 2021
  51. VINEREANU D, Napalkov D, Bergler-Klein J, Benczur B, et al
    Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    J Thromb Thrombolysis. 2021 Apr 30. pii: 10.1007/s11239-021-02450.
    PubMed     Abstract available

  52. BARTOLAZZI F, Ribeiro ALP, de Sousa WJFN, Vianna MS, et al
    Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study.
    J Thromb Thrombolysis. 2021 Apr 15. pii: 10.1007/s11239-021-02432.
    PubMed     Abstract available

    February 2021
  53. GAVIN O, Grandes J, Garcia MA, Marzo C, et al
    Treatment preferences as basis for decision making in patients using direct oral anticoagulants in Spain.
    J Thromb Thrombolysis. 2021;51:475-484.
    PubMed     Abstract available

    January 2021
    Highlights from the European society of cardiology congress 2020.
    J Thromb Thrombolysis. 2021;51:232-236.

    July 2020
  55. DIEP R, Garcia D
    Should we monitor the direct oral anticoagulants?
    J Thromb Thrombolysis. 2020;50:30-32.

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.